These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22101352)

  • 101. Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance.
    Niskakoski A; Pasanen A; Lassus H; Renkonen-Sinisalo L; Kaur S; Mecklin JP; Bützow R; Peltomäki P
    Mod Pathol; 2018 Aug; 31(8):1291-1301. PubMed ID: 29588532
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
    Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
    Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
    Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
    [TBL] [Abstract][Full Text] [Related]  

  • 107. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.
    Cunningham JM; Winham SJ; Wang C; Weiglt B; Fu Z; Armasu SM; McCauley BM; Brand AH; Chiew YE; Elishaev E; Gourley C; Kennedy CJ; Laslavic A; Lester J; Piskorz A; Sekowska M; Brenton JD; Churchman M; DeFazio A; Drapkin R; Elias KM; Huntsman DG; Karlan BY; Köbel M; Konner J; Lawrenson K; Papaemmanuil E; Bolton KL; Modugno F; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):132-141. PubMed ID: 34697060
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
    Maeda O; Miyata-Takata T; Shibata K; Kajiyama H; Mizuno M; Tamakoshi K; Shimoyama Y; Nakamura S; Kikkawa F
    Cancer Med; 2016 Jun; 5(6):1081-92. PubMed ID: 26993048
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
    Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
    Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes.
    Tsunematsu R; Murai A; Mizue Y; Kubo T; Mariya T; Morita R; Murata K; Kanaseki T; Tsukahara T; Hirohashi Y; Saito T; Torigoe T
    Cancer Genomics Proteomics; 2024; 21(4):414-420. PubMed ID: 38944423
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.
    Kuhn E; Meeker AK; Visvanathan K; Gross AL; Wang TL; Kurman RJ; Shih IeM
    Mod Pathol; 2011 Aug; 24(8):1139-45. PubMed ID: 21499239
    [TBL] [Abstract][Full Text] [Related]  

  • 112. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
    Köbel M; Xu H; Bourne PA; Spaulding BO; Shih IeM; Mao TL; Soslow RA; Ewanowich CA; Kalloger SE; Mehl E; Lee CH; Huntsman D; Gilks CB
    Mod Pathol; 2009 Mar; 22(3):469-75. PubMed ID: 19136932
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
    Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
    JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
    [TBL] [Abstract][Full Text] [Related]  

  • 114. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.
    Franklin M; Gentles L; Matheson E; Bown N; Cross P; Ralte A; Gilkes-Immeson C; Bradbury A; Zanjirband M; Lunec J; Drew Y; O'Donnell R; Curtin NJ
    Cancer Med; 2018 Sep; 7(9):4744-4754. PubMed ID: 30109783
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
    Itamochi H; Kigawa J; Terakawa N
    Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
    Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
    Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma.
    Saito R; Kuroda T; Yoshida H; Sudo K; Saito M; Tanabe H; Takano H; Yamada K; Kiyokawa T; Yonemori K; Kato T; Okamoto A; Kohno T
    Jpn J Clin Oncol; 2023 Aug; 53(9):781-790. PubMed ID: 37248674
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
    Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
    J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.